Analyzing Orchestra BioMed (OBIO) & Its Peers

Orchestra BioMed (NASDAQ:OBIO) is one of 227 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Orchestra BioMed to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Valuation and Earnings

This table compares Orchestra BioMed and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	-$49.12 million	-3.17
Orchestra BioMed Competitors	$1.06 billion	$4.84 million	-8.07

Orchestra BioMed’s competitors have higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Orchestra BioMed has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Orchestra BioMed’s competitors have a beta of 1.12, suggesting that their average stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Orchestra BioMed and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-1,779.71%	-58.32%	-41.47%
Orchestra BioMed Competitors	-742.46%	-147.54%	-29.28%

Insider and Institutional Ownership

53.6% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 48.3% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.7% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Orchestra BioMed and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	2	0	3.00
Orchestra BioMed Competitors	1581	4275	8360	220	2.50

Orchestra BioMed presently has a consensus price target of $17.00, suggesting a potential upside of 257.89%. As a group, “Surgical & medical instruments” companies have a potential upside of 28.87%. Given Orchestra BioMed’s stronger consensus rating and higher possible upside, equities analysts clearly believe Orchestra BioMed is more favorable than its competitors.

Summary

Orchestra BioMed competitors beat Orchestra BioMed on 7 of the 12 factors compared.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.